NIKKEI 225
27,466.61 +520.94 (+1.93%) HANG SENG
19,591.43 +332.67 (+1.73%) CRUDE OIL
70.32 +0.65 (+0.93%) GOLD FUTURES
1,971.00 +29.90 (+1.54%) DOW
32,108.35 -452.25 (-1.39%) Bitcoin GBP
21,822.60 -1,148.58 (-5.00%)
Atai Life Sciences N.V. (ATAI)
| Previous close | 1.2300 |
| Open | 1.2600 |
| Bid | 1.1900 x 4000 |
| Ask | 1.2000 x 2200 |
| Day's range | 1.1700 - 1.2400 |
| 52-week range | 1.1400 - 5.6000 |
| Volume | |
| Avg. volume | 1,417,040 |
| Market cap | 194.903M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2900 |
| Earnings date | 10 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.55 |
- Globe Newswire
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r
- Globe Newswire
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc
- Globe Newswire
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta
